Nicola Maguire

Cooley advised EyeBiotech Limited, a privately held, clinical-stage ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases, on the close of an extension to its Series A financing, bringing the total raised to date to $130 million.

Advising late-stage biotechnology company Immunocore on its $312.1 million aggregate financing, which consisted of a $297.1 million initial public offering of 11,426,280 American Depository Shares, including the full exercise of the underwriters’ option to purchase additional ADSs, and a $15 million concurrent private placement with the Bill & Melinda Gates Foundation.

Cooley advised CEPI (Coalition for Epidemic Preparedness Innovations), on its partnership with VBI Vaccines Inc., to develop VBI’s vaccine candidates against Covid-19 variants including that first identified from South Africa.

Cooley advised Immunocore on its $297.1 million initial public offering of 11,426,280 American depositary shares, which includes the full exercise of the underwriters’ option to purchase additional shares. Immunocore, whose securities now trade on the Nasdaq Global Market under the symbol IMCR, is a late-stage biotechnology company pioneering the development of a novel class of T-cell receptor bispecific immunotherapies designed to treat a broad range of diseases. Partners Div Gupta, Eric Blanchard, Nicola Maguire and Claire Keast-Butler led the Cooley team.

Cooley advised Singapore-headquartered Genesis MedTech International on its acquisition of the Chocolate Touch drug-coated balloon from TriReme Medical, a wholly owned subsidiary of Singapore-listed QT Vascular. The Chocolate Touch drug-coated balloon is the world's first balloon catheter that combines therapeutic agent delivery with the next generation of controlled dilation angioplasty technique for the treatment of peripheral vascular diseases. Cooley partners Lila Hope and Matthew Bartus led the team advising Genesis MedTech.